Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Market Closed 09-25 16:00:00 EDT

3.92

+0.20

+5.24%

盘后3.96

+0.04+1.15%

19:30 EDT

High4.00	Low3.66	Vol923.82K
Open3.75	D1 Closing3.72	Amplitude9.14%
Mkt Cap122.50M	Tradable Cap72.01M	Total Shares31.29M
T/O3.57M	T/O Rate5.02%	Tradable Shares18.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":3.915,"timestamp":1790366400000,"preClose":3.72,"halted":0,"volume":923818,"hourTrading":{"tag":"盘后","latestPrice":3.96,"preClose":3.915,"latestTime":"19:30 EDT","volume":6448,"amount":25286.225,"timestamp":1790379005029,"change":0.045,"changeRate":0.011494,"amplitude":0.011494},"delay":0,"changeRate":0.05241935483870963,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Market Closed","change":0.195,"latestTime":"09-25 16:00:00 EDT","open":3.75,"high":4,"low":3.66,"amount":3567717.3077587998,"amplitude":0.091398,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1790582400000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":3.72,"preHourTrading":{"tag":"盘前","latestPrice":3.8,"preClose":3.72,"latestTime":"08:26 EDT","volume":2532,"amount":9576.7261236,"timestamp":1790339195802,"change":0.08,"changeRate":0.021505,"amplitude":0.040323},"postHourTrading":{"tag":"盘后","latestPrice":3.96,"preClose":3.915,"latestTime":"19:30 EDT","volume":6448,"amount":25286.225,"timestamp":1790379005029,"change":0.045,"changeRate":0.011494,"amplitude":0.011494},"volumeRatio":1.2165088011917498,"impliedVol":2.4305,"impliedVolPercentile":0.8606},"requestUrl":"/m/hq/s/LENZ/wiki","defaultTab":"wiki","newsList":[{"id":"2670147147","title":"Southern Copper, Toll Brothers, Spruce Power, Structure Therapeutics, Verisign Insider Shake-Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2670147147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670147147?lang=en_us&edition=fundamental","pubTime":"2026-09-26 21:01","pubTimestamp":1790427702,"startTime":"0","endTime":"0","summary":"Insiders have been trading these 5 stocks: (($SCCO)), (($TOL)), (($SPRU)), (($GPCR)) and (($VRSN)). Here is a breakdown of their recent trades and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/weekend-updates/southern-copper-toll-brothers-spruce-power-structure-therapeutics-verisign-insider-shake-up?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/weekend-updates/southern-copper-toll-brothers-spruce-power-structure-therapeutics-verisign-insider-shake-up?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TOL","DBB","BK4088","BK4139","COPX","LENZ","PICK","BK4588","BK4007","SETM","LU0054578231.USD","ITB","BK4585","BK4539","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670787427","title":"Vector Science and Therapeutics Grants Stock Options to Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2670787427","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670787427?lang=en_us&edition=fundamental","pubTime":"2026-09-26 07:09","pubTimestamp":1790377769,"startTime":"0","endTime":"0","summary":"An announcement from Vector Science and Therapeutics Corp. ( ($TSE:PAIN) ) is now available. Vector Science and Therapeutics Corp., a Mequon-based ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/vector-science-and-therapeutics-grants-stock-options-to-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/vector-science-and-therapeutics-grants-stock-options-to-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","VAQC","BK4561","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670537422","title":"Silexion Therapeutics Shareholders Reject Capital Structure Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2670537422","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670537422?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:57","pubTimestamp":1790369829,"startTime":"0","endTime":"0","summary":"Silexion Therapeutics ( ($SLXN) ) just unveiled an update. On September 23, 2026, Silexion Therapeutics Corp reconvened its extraordinary general m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-shareholders-reject-capital-structure-changes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-shareholders-reject-capital-structure-changes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670225834","title":"Stoke Therapeutics appoints new independent board director","url":"https://stock-news.laohu8.com/highlight/detail?id=2670225834","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670225834?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:55","pubTimestamp":1790369758,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics ( ($STOK) ) just unveiled an update. On September 22, 2026, Stoke Therapeutics director Edward M. Kaye, M.D. informed the board ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/stoke-therapeutics-appoints-new-independent-board-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/stoke-therapeutics-appoints-new-independent-board-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670422327","title":"Silexion Therapeutics Receives Nasdaq Bid Price Deficiency Notice","url":"https://stock-news.laohu8.com/highlight/detail?id=2670422327","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670422327?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:50","pubTimestamp":1790369419,"startTime":"0","endTime":"0","summary":"The latest update is out from Silexion Therapeutics ( ($SLXN) ). On September 25, 2026, Silexion Therapeutics received a notice from Nasdaq’s Listi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-receives-nasdaq-bid-price-deficiency-notice?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/silexion-therapeutics-receives-nasdaq-bid-price-deficiency-notice?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NQmain","LENZ","BK4007","LCLG","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670142478","title":"Tempest Therapeutics files to sell 9.53M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2670142478","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670142478?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:35","pubTimestamp":1790368521,"startTime":"0","endTime":"0","summary":"This filing relates to the offer and sale from time to time by the selling stockholders of up to 9.53M shares of common stock. The company is not s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-9-53m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-files-to-sell-9-53m-shares-of-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670424103","title":"NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2670424103","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670424103?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:33","pubTimestamp":1790368406,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/62007928/neurosense-therapeutics-h1-eps-2-10-3-70-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670429188","title":"Trevi Therapeutics' Sample Size Re-estimation for Chronic Cough Trial Likely Positive, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670429188","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670429188?lang=en_us&edition=fundamental","pubTime":"2026-09-26 01:51","pubTimestamp":1790358664,"startTime":"0","endTime":"0","summary":"Trevi Therapeutics'  upcoming sample size re-estimation for its phase 2b trial of Haduvio in refractory chronic cough is expected to yield positive results, Oppenheimer said in a note Friday.The brokerage said it would consider a recommendation to continue the trial without any changes or increase enrollment as positive, with the upsizing scenario simply serving to increase the chance of showing statistical significance.RBC said it would be surprised if the check results in futility, given Haduvio's clinical record across chronic cough settings. In case this happens, data from idiopathic pulmonary fibrosis-related cough studies would offer downside protection, the brokerage said.The sample size re-estimation analysis is anticipated in Q4, with management expected to provide definitive guidance with its Q3 financial results, according to the note.Oppenheimer has an outperform rating on the stock, with a price target of $25.Price: 14.40, Change: -0.28, Percent Change: -1.87","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TRVI","LENZ","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670440538","title":"Analysts Offer Insights on Healthcare Companies: Damora Therapeutics (DMRA) and Nanobiotix (NBTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670440538","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670440538?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:30","pubTimestamp":1790339445,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Damora Therapeutics (DMRA) and Nanobiotix (NBTX) wit...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-nanobiotix-nbtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-damora-therapeutics-dmra-and-nanobiotix-nbtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DMRA","BK4588","BK4007","BK4139","XLV","LU0029874061.USD","BK4585","HCSG","NBTX","XBI","LENZ","BK4137","LABU","BK4581","BK4539","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670447260","title":"Damora Therapeutics price target raised, named a Best Idea at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2670447260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670447260?lang=en_us&edition=fundamental","pubTime":"2026-09-25 20:15","pubTimestamp":1790338523,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Brad Canino raised the firm’s price target on Damora Therapeutics (DMRA) to $60 from $40 and keeps a Buy rating on the shares, w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-price-target-raised-named-a-best-idea-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/damora-therapeutics-price-target-raised-named-a-best-idea-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670838444","title":"Thalia Therapeutics Completes Initial Synthesis for Cardiovascular siRNA Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2670838444","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670838444?lang=en_us&edition=fundamental","pubTime":"2026-09-25 18:18","pubTimestamp":1790331514,"startTime":"0","endTime":"0","summary":"Thalia Therapeutics completed the initial chemistry synthesis of its siRNA candidate THAT-002, according to a Friday filing on London Stock Exchange.The company began preclinical work on THAT-002 with WuXi AppTec's  WuXi AppTec  in September. The candidate is designed to target PCSK9 and lipoprotein, two factors associated with cardiovascular disease risk.Thalia will now begin in vitro studies, followed by in vivo studies later in the Q4. Data from the studies will guide further preclinical development ahead of IND-enabling studies and potential human trials.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2242644610.SGD","BK1141","LU0052750758.USD","LU1979443071.USD","LU2495084118.USD","LU1046422090.SGD","LU1303224171.USD","LU2125910500.SGD","LU0456842615.SGD","LU0469268626.HKD","LU1808992512.USD","LU1997245177.USD","BK4007","BK4539","LU0348767384.USD","LU0611395673.USD","LU1719994722.HKD","LU1934453819.USD","BK0216","LU2045819591.USD","BK1576","LU2328871848.SGD","LU0708995583.HKD","LU0572944931.SGD","LU0320764599.SGD","LU1997244956.HKD","LENZ","BK4082","LU0327786744.USD","IE00B5MMRT66.SGD","BK1583","LU1997245094.SGD","IE00BPRC5H50.USD","IE00B543WZ88.USD","LU1770034418.SGD","LU0700851271.USD","02359","603259","CSII","LU1969619763.USD","LU2488822045.USD","LU1251922891.USD","LU0348766576.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670175454","title":"Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2670175454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670175454?lang=en_us&edition=fundamental","pubTime":"2026-09-25 11:57","pubTimestamp":1790308676,"startTime":"0","endTime":"0","summary":"An announcement from Alterity Therapeutics ( ($AU:ATH) ) is now available. Alterity Therapeutics has scheduled its next Annual General Meeting for ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-sets-2026-agm-date-and-director-nomination-deadline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alterity-therapeutics-sets-2026-agm-date-and-director-nomination-deadline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4539","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670413651","title":"City Therapeutics Files for IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2670413651","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670413651?lang=en_us&edition=fundamental","pubTime":"2026-09-25 05:00","pubTimestamp":1790283600,"startTime":"0","endTime":"0","summary":"City Therapeutics filed for an initial public offering.The biotechnology company, which focuses on RNA interference therapeutics, didn't say how many shares it would offer or at what price, according to a Thursday filing with the Securities and Exchange Commission.City currently has five therapeutics in its pipeline, including two being developed in partnerships with Biogen and with Bausch + Lomb. Its most advanced candidate, CITY-FXI, is being developed as a thrombosis treatment and is currently in a Phase 1 trial.The company plans to use proceeds from the IPO to support its platform and the clinical development of its pipeline drugs, including the initiation of a Phase 2 study.It applied to list shares on the Nasdaq Global Market under the symbol CTY.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","LENZ","KCE","BK4139","BK4007","IPOS","REDS","CHCO","BK4539","BK4127","FRHC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670141836","title":"Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2670141836","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670141836?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:05","pubTimestamp":1790280300,"startTime":"0","endTime":"0","summary":"RADNOR, Pa., Sept.  24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368738/0/en/mineralys-therapeutics-to-participate-in-the-stifel-2026-virtual-cardiometabolic-forum.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4179","FET","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670334418","title":"Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert","url":"https://stock-news.laohu8.com/highlight/detail?id=2670334418","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670334418?lang=en_us&edition=fundamental","pubTime":"2026-09-25 04:01","pubTimestamp":1790280060,"startTime":"0","endTime":"0","summary":"Keli Walbert brings two decades of commercial leadership and proven track record of successful launches to the BoardCAMBRIDGE, Mass. and COPENHAGEN, Denmark, Sept.  24, 2026 (GLOBE NEWSWIRE) -- Hemab ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368728/0/en/hemab-therapeutics-strengthens-board-of-directors-with-appointment-of-keli-walbert.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670949064","title":"Arcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2670949064","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670949064?lang=en_us&edition=fundamental","pubTime":"2026-09-25 03:08","pubTimestamp":1790276936,"startTime":"0","endTime":"0","summary":"Arcturus Therapeutics (ARCT) shares rose 6.3% in Thursday afternoon trading, a day after it reported interim phase 2 results for ARCT-810 in OTC deficiency and unveiled LUNAR 2.0, its next-generation ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670492787","title":"Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2670492787","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670492787?lang=en_us&edition=fundamental","pubTime":"2026-09-25 01:02","pubTimestamp":1790269368,"startTime":"0","endTime":"0","summary":"Oruka Therapeutics'  lead program of long-acting IL-23 in moderate-to-severe psoriasis maintains a \"competitive profile\" after positive week 28 clinical data, UBS said in a Wednesday note.Oruka's ORKA-001 increased its Psoriasis Area and Severity Index-100 score, which represents the complete resolution of psoriasis, to 71% from 64% in week 16. This compares favorably with rival product, AbbVie's  Skyrizi, which rose to 53% from 43% in the same period, UBS analysts said.The safety data was also consistent with prior data, as treatment-emergent adverse events were 36% in the period of week 16 to 28, compared with 51% during week zero to 16. There were also no injection site reactions and no impact of anti-drug antibodies on safety, efficacy and pharmacokinetics, the analysts noted.The analysts said they are confident in the company's multiple additional readouts later in the year to be positive, \"given the de-risking provided by previous datasets\".UBS' rating on the company's stock is b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2129689514.USD","LU0114720955.EUR","LU0320765646.SGD","FHLC","AGNG","LU0256863902.USD","SG9999015986.USD","IE000WAW04H5.SGD","IE00BLSP4239.USD","GLAM","LU0211327993.USD","BK4550","LU0395794307.EUR","ORKA","IE00BN8TJ469.HKD","LU1003077747.HKD","LU2237443549.SGD","IXJ","IE00BVYPNW00.USD","LU0029864427.USD","ABBV","JDOC","LU0511384066.AUD","PPH","IE000F7OJYX1.SGD","IE00BSNM7G36.USD","MEDX","BK4588","VHT","BK4007","IYH","PJP","LU0198837287.USD","SG9999001440.SGD","BK4585","IE00B19Z3B42.SGD","XLV","RXL","LU0124676726.USD","LENZ","LU1934455863.HKD","LU2133065610.SGD","LU0985320562.USD","LU0795875169.SGD","LU0256863811.USD","LU0432979614.USD","LU0289961442.SGD","TRUH","FTXH","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670249408","title":"Tempest Therapeutics is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2670249408","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670249408?lang=en_us&edition=fundamental","pubTime":"2026-09-25 00:06","pubTimestamp":1790265960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TPST/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669941234","title":"Arcturus Therapeutics Raised to Buy from Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2669941234","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669941234?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:56","pubTimestamp":1790265360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARCT/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669310494","title":"Tempest Therapeutics price target lowered to $7 from $11 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2669310494","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669310494?lang=en_us&edition=fundamental","pubTime":"2026-09-24 23:22","pubTimestamp":1790263330,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Tempest Therapeutics (TPST) to $7 from $11 and keeps a Buy rating on th...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-price-target-lowered-to-7-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempest-therapeutics-price-target-lowered-to-7-from-11-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":-0.181},{"period":"3month","weight":-0.3273},{"period":"6month","weight":-0.5339},{"period":"1year","weight":-0.9022},{"period":"ytd","weight":-0.7553}],"compareEarnings":[{"period":"1week","weight":0.0127},{"period":"1month","weight":0.0069},{"period":"3month","weight":0.0581},{"period":"6month","weight":0.2165},{"period":"1year","weight":0.1722},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.5,"avgChangeRate":-0.019031},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}